The hospitalist at Memorial Sloan Kettering Cancer Center discussed the results of a study which evaluated the use of 177Lu-DOTATATE in patients with well-differentiated, high-grade neuroendocrine tumors.
Investigators observed a meaningful disease control rate among patients with well-differentiated, high-grade neuroendocrine tumors (NETs) who were treated with 177Lu-DOTATATE (Lutathera), according to study results presented at the 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.
In an interview with CancerNetwork®, Kelley Lauren Coffman, MD, a hospitalist at Memorial Sloan Kettering Cancer Center, spoke about the results of the study and the toxicities she and her colleagues observed during the trial.
In the predominant results, we saw that there was good benefit in terms of disease stability from the treatment. About 63% of patients had a partial response to the therapy after completing 4 cycles, about 6% had stable disease, and unfortunately about a third of the patients, about 31%, did progress.
The other notable results were the toxicities. It was consistent with what was seen in the earlier trials, where the primary toxicity was bone marrow suppression and [aspartate aminotransferase; AST]/[alanine aminotransferase; ALT] elevation. But the severity in our patient population was not quite that high. We didn’t really see any grade 3 or grade 4 toxicities.
Coffman KL, Bodei L, Le T, et al. Treatment response and clinical outcomes of well-differentiated high-grade neuroendocrine tumors to 177Lu-DOTATATE. J Clin Oncol. 2021;39(suppl 3). Abstract #: 368.